Entity

Time filter

Source Type

Fuchū, Japan

Patent
Kewpie Corporation | Date: 2010-12-01

Provided a method of producing a purified hyaluronic acid type which comprises adding a water-soluble organic medium to a solution which comprises a hyaluronic acid type having an average molecular weight of 400 to 100,000 and has a pH of 3 or less to obtain a suspension, and adjusting a pH of the suspension in a range of 3.5 to 8 to precipitate a purified hyaluronic acid type.


Patent
Kewpie Corporation, Cargill Inc. and Bespack Corporation | Date: 2012-02-15

Provided is a pull-top style discharge member for a package to be mounted on a dispenser. The package discharge member is provided with an outer frame


Provided an acidic oil-in-water type emulsified seasoning comprising a cross-linked starch, the content of oils and fats is 10 to 70 mass %, the viscosity is 20,000 to 1,000,000 mPas, a first peak is present in the range of 0.5 to 5 micrometers and a second peak is present in the range of 20 to 80 micrometers in a particle size distribution of the acidic oil-in-water type emulsified seasoning measured by using a laser diffraction particle size analyzer, and the cross-linked starch has the following characteristics: Condition: a mixture of the cross-linked starch and water comprising 8 mass % of the cross-linked starch is heated up to 90 C., and then is maintained at 90 C. for 5 minutes, and then is cooled to 20 C., and then is stirred with a homomixer at 10,000 rpm for 5 minutes.


Patent
Kewpie Corporation | Date: 2010-08-10

Provided an acidic oil-in-water type emulsified seasoning comprising egg yolk, the content of oils and fats is 10 to 40 mass %, and the oscillating strain and the loss elastic modulus (G), which are indicative of dynamic viscoelasticity measured by the following condition with a rheometer, have the following relationship.


An oral preparation for promoting expression of TGF- includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation promoting expression of TGF- in plasma. In addition, an oral preparation for suppressing production of a pain-producing substance includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation suppressing production of a pain-producing substance by promoting expression of TGF- in plasma. In addition, an oral preparation for suppressing production of a pain-producing substance includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation suppressing production of a pain-producing substance PGE2 and/or bradykinin. In addition, an oral preparation for suppressing edema includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation suppressing production of a pain-producing substance PGE2 and/or bradykinin.

Discover hidden collaborations